CCL2 and cancer: Subsequently, Fujisaki et al. confirmed the findings of Dirat et al. in CAAs which were derived from BC patients, and further found that CAAs decreased in size and exhibited an immature and proliferative phenotype in the presence of cancer cells, and contributed to cancer cell migration via adipokines including IL- 6 and MCP-1 [23].